Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: A combined MRI and clinical approach

American Journal of Roentgenology

Volumn 200, Issue 4, 2013, Pages

  Schanz, Stefan ^a   Henes, Jorg ^a   Ulmer, Anja ^a   Kotter, Ina ^a   Fierlbeck, Gerhard ^a   Claussen, Claus Detlef ^a   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fasciitis; Localized scleroderma; Localized scleroderma severity index; Morphea; MRI; Myositis; Skin induration

Indexed keywords

FOLIC ACID; GADOBUTROL; GADOLINIUM PENTETATE MEGLUMINE; METHOTREXATE; PREDNISOLONE; CONTRAST MEDIUM; DERMATOLOGICAL AGENT; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; GLUCOCORTICOID;

ADULT; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; ENTHESITIS; FASCIA; FEMALE; FOLLOW UP; HUMAN; MALE; MORPHEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PAIN ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SUBCUTANEOUS FAT; SYNOVITIS; SYNOVIUM; SYSTEMIC SCLEROSIS; TENDON; TENOSYNOVITIS; TREATMENT RESPONSE; WHOLE BODY MRI; LOCALIZED SCLERODERMA; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; TREATMENT OUTCOME;

ADULT; CONTRAST MEDIA; DERMATOLOGIC AGENTS; FEMALE; GADOLINIUM DTPA; GLUCOCORTICOIDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; SCLERODERMA, LOCALIZED; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84878231399     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9335     Document Type: Article

References (29)

1. [No authors listed]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590
2. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18: 606-613
3. Tekin NS, Altinyazar HC, Tekin IO, Keskin SI, Kucukoglu R, Onsun N. Disabling pansclerotic morphoea: a case report. Int J Clin Pract 2010; 64: 99-101
4. Kroft EB, de Jong EM, Evers AW. Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Arch Dermatol 2008; 144: 1394-1395
5. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 2009; 48: 1410-1413
6. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52: 2873-2881
7. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children - an international study. Rheumatology (Oxford) 2006; 45: 614-620
8. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008; 59: 385-396
9. Leitenberger JJ, Cayce RL, Haley RW, Adams- Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009; 145: 545-550
10. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxmer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-95
11. Czarnecki DB, Taft EH. Generalized morphoea successfully treated with salazopyrine. Acta Derm Venereol 1982; 62: 81-82
12. Wach F, Ullrich H, Schmitz G, Landthaler M, Hein R. Treatment of severe localized scleroderma by plasmapheresis: report of three cases. Br J Dermatol 1995; 133: 605-609
13. Falanga V, Medsger TA Jr. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126: 609-612
14. Kerscher M, Meurer M, Sander C, et al. PUVA bath photochemotherapy for localized scleroderma: evaluation of 17 consecutive patients. Arch Dematol 1996; 132: 1280-1282
15. Kerscher M, Volkenandt M, Gruss C, et al. Lowdose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38: 21-26
16. Rocken M. Ghoreschi K. Morphea and lichen sclerosus. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. St Louis, MO: Mosby, 2003: 1503- 1517
17. Kreuter A, Krieg T, Worm M, et al. AWMF guideline no. 013/066: diagnosis and therapy of circumscribed scleroderma [in German]. J Dtsch Dermatol Ges 2009; 6(suppl 6):S1-S14
18. Seyger MM, van den Hoogen FH, van Vlijmen- Willems IM, van de Kerkhof PC, de Jong EM. Localized and systemic scleroderma show different histological responses to methotrexate therapy. J Pathol 2001; 193: 511-516
19. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141: 847-852
20. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, sideeffects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 2009; 160: 1075-1082
21. Fitch PG, Rettig P, Burnham JM, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006; 33: 609-614
22. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006; 155: 1013-1020
23. Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63: 1998-2006
24. Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single- center study. J Rheumatol 2012; 39: 286-294
25. Schanz S, Fierlbeck G, Ulmer A, et al. Localized scleroderma: MR findings and clinical features. Radiology 2011; 260: 817-824
26. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068-1076
27. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 2008; 35: 650-657
28. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009; 36: 2819-2829
29. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007; 46: 856-860